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Background. The spread of Klebsiella pneumoniae (Kp) strains that produce K. pneumoniae carbapenemases
(KPCs) has become a signiﬁcant problem, and treatment of infections caused by these pathogens is a major chal-
lenge for clinicians.
Methods. In this multicenter retrospective cohort study, conducted in 3 large Italian teaching hospitals, we
examined 125 patients with bloodstream infections (BSIs) caused by KPC-producing Kp isolates (KPC-Kp) diag-
nosed between 1 January 2010 and 30 June 2011. The outcome measured was death within 30 days of the ﬁrst
positive blood culture. Survivor and nonsurvivor subgroups were compared to identify predictors of mortality.
Results. The overall 30-day mortality rate was 41.6%. A signiﬁcantly higher rate was observed among patients
treated with monotherapy (54.3% vs 34.1% in those who received combined drug therapy; P = .02). In logistic
regression analysis, 30-day mortality was independently associated with septic shock at BSI onset (odds ratio
[OR]: 7.17; 95% conﬁdence interval [CI]: 1.65–31.03; P = .008); inadequate initial antimicrobial therapy (OR: 4.17;
95% CI: 1.61–10.76; P = .003); and high APACHE III scores (OR: 1.04; 95% CI: 1.02–1.07; P < .001). Postantibio-
gram therapy with a combination of tigecycline, colistin, and meropenem was associated with lower mortality
(OR: 0.11; 95% CI: .02–.69; P = .01).
Conclusions. KPC-Kp BSIs are associated with high mortality. To improve survival, combined treatment with
2 or more drugs with in vitro activity against the isolate, especially those also including a carbapenem, may be
more effective than active monotherapy.
The production of Klebsiella pneumoniae (Kp) strains
that produce K. pneumoniae carbapenemases (KPCs) by
Enterobacteriaceae has become a signiﬁcant problem in
terms of public health and clinical outcome. KPC-
producing strains are not only able to hydrolyze carba-
penems, they are often resistant to a variety of other an-
tibiotics as well. Effective treatment of infections caused
by these pathogens is thus a considerable challenge for
clinicians [1–3].
KPC-producing Enterobacteriaceae have caused nu-
merous infection outbreaks in the northeastern United
States, Israel, and Greece, where they are now consid-
ered endemic [1, 2, 4–6]. Most of the reports on these
outbreaks have analyzed the molecular epidemiologi-
cal aspects or the in vitro antimicrobial susceptibility
proﬁles of the isolates: less attention has been focused
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on the drugs used to treat the infections and patient outcomes
[7–12]. Small clinical studies have revealed high treatment
failure rates associated with these infections, and reported
mortality rates range from 22% to 72% [10, 13]. Treatment
options are usually limited to colistin, gentamicin, and/or tige-
cycline [14], but the optimal regimen for infections caused by
KPC-producing bacteria has yet to be deﬁned. A recent analy-
sis of 55 cases found that treatment with tigecycline or with
an aminoglycoside was generally associated with positive out-
comes [10]. Moreover, descriptive reports of outbreaks of in-
fections caused by KPC producers indicate that combination
therapies are often more effective than monotherapies [15,
16], and this conclusion is supported by in vitro data [17].
Identifying the best treatment regimen for these infections will
require larger studies with more in-depth analysis of clinical
characteristics and outcomes.
In this multicenter, hospital-based study, we attempted to
pinpoint risk factors for mortality in a cohort of 125 patients
with bloodstream infections (BSIs) caused by KPC-producing
isolates of Kp (KPC-Kp). Particular attention was focused on
the impact of antimicrobial regimens used in the nonempirical
phase of treatment.
MATERIALS AND METHODS
Setting
The study was conducted in 3 large Italian teaching hospitals
that offer a full range of clinical services. Each facility admits
approximately 50 000 patients per year. Surveillance cultures
were not routinely performed during the study period.
Study Design and Patients
We searched each hospital’s central microbiology laboratory
database to identify cases with all of the following characteris-
tics: KPC-Kp BSI diagnosed between 1 January 2010 and 30
June 2011; patient age ≥18 years; absence of bloodstream iso-
lates other than Kp; no evidence of non-Kp infections at other
sites; and treatment of the BSI for at least 48 hours (empirical-
ly and/or based on antibiogram data) with ≥1 antimicrobial
displaying in vitro activity against the KPC-Kp isolate [15].
Recurrent infections were excluded; only the ﬁrst KPC-Kp BSI
episode per patient was included in our analysis. A retrospec-
tive cohort study design was employed. The outcome mea-
sured was death within 30 days of the ﬁrst positive blood
culture. Survivor and nonsurvivor subgroups were compared
to identify predictors of mortality.
Variables Explored as Possible Predictors of Mortality
Patient variables included age, sex, Charlson Comorbidity
Index [18], underlying diseases, immunosuppressive therapy,
duration of index hospitalization, and BSI onset in an
intensive care unit. We also considered histories of previous
hospitalization (≤12 months before BSI onset), surgery (≤30
days before BSI onset), invasive procedures performed ≤72
hours before BSI onset (insertion of central venous catheters,
nasogastric tubes, or Foley catheters; endoscopy; endoscopic
retrograde cholangiopancreatography; bronchoscopy; paren-
teral nutrition; mechanical ventilation), and antimicrobial
therapy being administered ≤30 days before BSI onset. Infec-
tion variables consisted of BSI presentation with septic shock,
severity of illness at infection onset, and source of infection.
Treatment variables included initial (ie, empirical) antimicro-
bial therapy that was inadequate (see Deﬁnitions) and the
number and type of drugs included in the postantibiogram
treatment regimen.
Deﬁnitions
The following terms were deﬁned prior to data analysis. A
KPC-Kp BSI was deﬁned as a BSI documented by blood-
culture positivity (at least 1 specimen) for a KPC-Kp strain
and clinical signs of the systemic inﬂammatory response syn-
drome [19]. BSI onset was deﬁned as the date of collection of
the index blood culture (ie, the ﬁrst blood culture that yielded
the study isolate). BSIs were deﬁned as hospital-acquired if the
index blood culture had been collected >48 hours after hospi-
tal admission and no signs or symptoms of infection had been
noted at admission. Infections with onset <48 hours after hos-
pital admission were classiﬁed as either healthcare-associated
or community-acquired, in accordance with the deﬁnitions of
Friedman et al [20]. Septic shock was deﬁned as sepsis associ-
ated with organ dysfunction and persistent hypotension
despite volume replacement [19]. Illness severity at baseline
was expressed in terms of the Acute Physiology and Chronic
Health Evaluation (APACHE) III score [21] calculated at the
time of BSI onset. An antimicrobial treatment regimen was
deﬁned as adequate when it included at least 1 drug displaying
in vitro activity against the KPC-producing Kp isolate. De-
pending on the number of in vitro–active drugs they included
(1 or >1), treatment regimens were classiﬁed as monotherapy
or combination therapy.
Microbiology, KPC Identiﬁcation, and Antimicrobial
Susceptibilities
The Vitek 2 automated system (bioMérieux, Marcy l’Etoile,
France) was used for isolate identiﬁcation and antimicrobial
susceptibility testing. Minimum inhibitory concentrations
(MICs) were classiﬁed according to Clinical and Laboratory
Standards Institute (CLSI) breakpoints [22], except those for
colistin, which were interpreted according to breakpoints es-
tablished by the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) (susceptible, MIC≤ 2 mg/L;
resistant, MIC > 2 mg/L) [23]. For tigecycline, the US Food
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and Drug Administration (FDA) recommendation was used
(susceptible, MIC≤ 2 mg/L; resistant, MIC≥ 8 mg/L) [24].
Ertapenem-resistant isolates were tested for carbapenemase
production in accordance with CLSI guidelines [25]. The pres-
ence of a blaKPC gene was determined by polymerase chain
reaction and sequencing, as previously described [26].
Statistical Analysis
Continuous variables were compared with Student t test (for
normally distributed variables) or the Mann-Whitney U test
(for nonnormally distributed variables). Categorical variables
were evaluated with the χ2 or 2-tailed Fisher exact test. Odds
ratios (ORs) and 95% conﬁdence intervals (CIs) were calculat-
ed for all associations that emerged. Results are expressed as
mean ± standard deviation (SD) or median (range) (continu-
ous variables) or as percentages of the group from which they
were derived (categorical variables). Two-tailed tests were used
to determine statistical signiﬁcance; a P value of < .05 was con-
sidered signiﬁcant. Multivariate analysis was used to identify
independent risk factors for mortality. For this analysis, we
used logistic regression, and variables found to be signiﬁcant
in univariate testing were incorporated with a stepwise ap-
proach. Survival distribution function was estimated using the
Kaplan-Meier product–limit method; nonparametric (log-rank
and Wilcoxon) tests were used to compare survival functions
in different groups. All statistical analyses were performed
with the Intercooled Stata software program, version 11.
RESULTS
Of the 413 Kp BSIs diagnosed during the study period, 147
(35.6%) were caused by KPC-producing isolates, and 125 of
these cases (96.8% hospital-acquired, and 3.2% healthcare-
associated infections) met the criteria for inclusion in our
study. Thirty days after BSI onset, 52 of the 125 patients
(41.6%) had died. The main characteristics of the survivor and
nonsurvivor subgroups are presented in Table 1.
Characteristics of KPC-Producing Isolates
Ninety-eight of the 125 (78.4%) conﬁrmed KPC-producing
isolates included in the study harbored the blaKPC-3 gene, and
the other 27 (21.6%) carried the blaKPC-2 gene. All 125 isolates
were resistant to penicillins, cephalosporins, ertapenem, cipro-
ﬂoxacin, amikacin, cotrimoxazole, and chloramphenicol. Mer-
openem MICs were consistently high: ≥16 mg/L for 78
(62.4%) isolates; 8 mg/L for 17 (13.6%) isolates; 4 mg/L for 16
(12.8%) isolates, 2 mg/L for 13 (10.4%) isolates, and 1 mg/L
for 1 (0.8%) isolate. Most isolates were susceptible to colistin
(n = 110, 88%), tigecycline (n = 114, 91.2%), and/or gentami-
cin (n = 118, 94.4%). Genotype-speciﬁc resistance rates for
these drugs are shown in Figure 1.
Antimicrobial Treatment
Within a few hours after index blood cultures were drawn, all
patients were being empirically treated with currently recom-
mended doses [27] of anti-gram-negative drugs (alone or with
other antibiotics). In most cases, the empirical regimen was
prescribed ad hoc by ward physicians without the aid of pre-
deﬁned protocols.
On the basis of antibiograms (reported 72–120 hours
[median 76 hours]) after BSI onset, more than half of the em-
pirical regimens (75/125, 60%) were classiﬁed as inadequate.
The ineffective drugs were ß-lactam–ß-lactamase inhibitor
combinations in 31 cases (41.3%), carbapenems in 25 (33.3%),
aminoglycosides in 8 (10.7%), ﬂuoroquinolones in 6 (8%), and
oxyimino-cephalosporins in 4 (5.3%).
All decisions on deﬁnitive therapy were made with the aid
of an infectious disease specialist. Loading doses were used
with colistin and tigecycline. Thereafter, the former drug was
given every 8–12 hours for a total daily dose of 6 000 000–
9 000 000 IU; the latter drug was administered every 12 hours
(100–200 mg/day). Gentamicin was given every 24 hours
(total daily dose 4–5 mg/kg), and meropenem was adminis-
tered by extended infusion (lasting ≥3 hours) at a dose of 2 g
every 8 hours. All dosages were adjusted on the basis of creat-
inine clearance if necessary. The overall median duration of
treatment was 16 (interquartile range [IQR]: 7–28) days.
As shown in Table 1, the postantibiogram regimen used for
46 patients (36.8%) consisted of a single drug. In the 22 pa-
tients who received colistin monotherapy, the colistin MICs
were ≤0.5 mg/L for 16 (72.7%) isolates and 1 mg/L for 6
(27.3%) isolates (all well within the EUCAST range of suscept-
ibility, ie, ≤2 mg/L). Similar ﬁndings emerged for the 19 pa-
tients treated with tigecycline alone (MICs were ≤0.5 mg/L for
5 [26.3%] isolates and 1 mg/L for 10 [52.6%] others), but in 4
(21.1%) of these cases the tigecycline MIC (2 mg/L) ap-
proached the upper limit of the FDA-deﬁned susceptibility
range. Most patients (63.2%) received ≥2 drugs with in vitro
activity against the KPC-Kp isolate. The most common com-
bination was colistin plus tigecycline, which was used in a
total of 39 cases, alone (n = 23) or with a third drug (merope-
nem) (n = 16). As shown in Table 2, single-drug regimens
(mainly colistin or tigecycline) were used more frequently for
BSIs that stemmed from urinary tract infections, whereas
combination therapy was signiﬁcantly more common in inten-
sive care unit patients and above all in patients whose Kp iso-
lates had suboptimal/borderline tigecycline and colistin MICs.
Outcomes and Mortality Predictors
The 52 (41.6%) patients who died within 30 days of BSI onset
included 25 of the 46 (54.3%) whose postantibiogram regi-
mens were classiﬁed as monotherapy and 27 of the 79 (34.1%)
who were on combination regimens (P = .02). The 30-day
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Table 1. Univariate Analysis of Factors Associated With Death Among Patients With Bloodstream Infections Due to Klebsiella
pneumoniae Carbapenemase–Producing K. pneumoniae
Variable
No. (%) of Patients
P Value OR (95% CI)Nonsurvivors (n = 52) Survivors (n = 73)
Univariate analysis
Demographic variables
Male sex 32 (61.5) 41 (56.2) .54 1.13 (.74–1.75)
Age, years, mean ± SD 61.5 ± 14.3 62.9 ± 16.5 .61 …
Ward
Medicine 18 (34.6) 26 (35.6) .90 0.97 (.62–1.50)
Surgery 12 (23.1) 16 (21.9) .87 1.03 (.63–1.69)
Intensive care unit 22 (42.3) 31 (42.5) .98 0.99 (.65–1.51)
LOS, days, median (IQR) 57 (29–63) 78 (36–90) .02 …
Previous hospitalizationa 38 (73.1) 29 (39.7) <.001 2.34 (1.42–3.88)
Previous bacterial infectionsb 25 (48.1) 33 (45.2) .75 1.06 (.70–1.62)
Invasive proceduresc 28 (53.8) 46 (63.1) .30 0.80 (.52–1.21)
Indwelling central venous catheter 40 (76.9) 48 (65.7) .17 1.40 (.83–2.35)
Indwelling urinary catheter 36 (69.2) 46 (63.1) .47 1.17 (.74–1.86)
Nasogastric tubec 18 (34.6) 17 (23.3) .16 1.36 (.89–2.06)
Surgical drainagec 11 (21.1) 17 (23.3) .77 0.92 (.55–1.55)
Previous surgeryd 18 (34.6) 25 (34.2) .96 1.01 (.65–1.56)
Immunosuppressive therapyd 10 (19.2) 6 (8.2) .06 1.62 (1.03–2.53)
Previous antibiotic therapyd 47 (90.4) 58 (79.4) .10 1.79 (.81–3.93)
Comorbidities
Diabetes mellitus 9 (17.3) 20 (27.4) .18 0.69 (.38–1.24)
Heart failure 12 (23.1) 12 (16.4) .35 1.26 (.79–2.01)
Chronic renal failure 6 (11.5) 6 (8.2) .53 1.22 (.66–2.25)
Solid tumor 10 (19.2) 15 (20.5) .85 0.95 (.55–1.62)
Hematological malignancy 7 (13.4) 6 (8.2) .34 1.34 (.77–2.32)
Charlson Comorbidity Index, median (IQR) 2 (0–4) 2 (0.5–2.5) .82 …
Postantibiogram antimicrobial regimens
Monotherapy 25 (48.1) 21 (28.7) .02 1.59 (1.06–2.38)
Tigecycline 10 (19.2) 9 (12.3) .28 1.32 (.81–2.16)
Colistin 11 (21.5) 11 (15.1) .37 1.25 (.77–2.03)
Gentamicin 4 (7.6) 1 (1.3) .09 1.98 (1.21–3.23)
Combination therapy 27 (51.9) 52 (71.2) .02 0.62 (.41–.94)
2-drug combinations 23 (44.2) 33 (45.2) .91 0.97 (.64–1.48)
Tigecycline + colistin 7 (13.4) 16 (21.9) .22 0.68 (.35–1.32)
Tigecycline + gentamicin 6 (11.5) 6 (8.2) .53 1.22 (.66–2.25)
Other 2-drug combinationse 10 (19.2) 11 (15.1) .54 1.17 (.71–1.95)
3-drug combinations 4 (7.7) 19 (26.1) .009 0.36 (.15–.92)
Tigecycline + colistin +meropenem 2 (3.8) 14 (19.2) .009 0.27 (.07–1.01)
Other 3-drug combinationsf 2 (3.8) 5 (6.8) .47 0.67 (.21–2.21)
Inadequate initial antimicrobial treatment 39 (75) 36 (49.3) .003 2.00 (1.19–3.34)
Presentation with septic shock 13 (25) 4 (5.5) .002 2.11 (1.47–3.04)
APACHE III score (mean ± SD) 40 ± 22 24 ± 15 <.001 …
Data are expressed as No. (%) unless otherwise specified.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CI, confidence interval; IQR, interquartile range; LOS,
length of hospital stay; OR, odds ratio; SD, standard deviation.
a During the 12 months preceding BSI onset.
b During the 3 months preceding BSI onset.
c During the 72 hours preceding BSI onset.
d During the 30 days preceding BSI onset.
e Colistin + gentamicin (n = 7); gentamicin +meropenem (n = 6); tigecycline +meropenem (n = 4); colistin +meropenem (n = 4).
f Tigecycline + gentamicin +meropenem (n = 6); colistin + gentamicin +meropenem (n = 1).
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survival distributions were also signiﬁcantly different in pa-
tients treated with monotherapy vs combination therapy
regimens (P = .002) (Figure 2). Mortality rates within the
combination regimen group were 30.4% (7/23) for those
treated with tigecycline plus colistin; 50% (6/12) for
those treated with tigecycline plus gentamicin; 57% (4/7)
for those treated with colistin plus gentamicin; 12.5% (2/16)
for those treated with tigecycline, colistin, and meropenem;
and 16.6% (1/6) for those treated with tigecycline, gentamicin,
and meropenem.
Univariate analysis revealed signiﬁcant differences between
the survivor and nonsurvivor subgroups. Patients in the latter
group were more likely to have recent histories of hospitaliza-
tion, immunosuppressive therapy, and/or chemotherapy;
higher APACHE III scores; and septic shock at BSI presenta-
tion. This group also had higher rates of inadequate empirical
therapy and of postantibiogram regimens that were classiﬁed
as monotherapy. Survivors were more likely to have received
combination therapy in the postantibiogram phase. The only
multidrug regimen that was signiﬁcantly more common in the
survivor group (P = .009) was the combination of tigecycline,
colistin, and meropenem (Table 1). Subgroup analysis of the
75 patients who received inappropriate empirical therapy
(overall mortality, 52%) revealed signiﬁcantly lower mortality
(14.3%) among the 14 whose deﬁnitive therapy consisted of
this triple-drug regimen.
Logistic regression analysis indentiﬁed septic shock at BSI
onset, inadequate initial antimicrobial therapy, and high
APACHE III scores as independent predictors of 30-day mortal-
ity, whereas combination therapy with tigecycline, colistin, and
meropenem was associated with a lower risk of mortality
(Table 3). In Table 4 the 30-day survival rates for the 36 patients
whose combination regimens included meropenem are stratiﬁed
according the meropenem MICs of their KPC-Kp isolate.
DISCUSSION
To the best of our knowledge, our study represents the largest
sample of KPC-Kp BSIs analyzed to date. Most of the isolates
recovered from our patients were susceptible to gentamicin,
colistin, and tigecycline. Resistance rates for the latter 2 drugs
(12% and 7.2%, respectively) were fairly consistent with previ-
ous reports [2, 5, 10, 11, 28–30].
Our ﬁndings also conﬁrm the high mortality associated
with these multidrug-resistant infections, with 41.6% of pa-
tients dying within 30 days of infection. This outcome was in-
dependently predicted by 3 factors. Two (ie, presence of septic
shock and high APACHE III score) were related to the clinical
status of the patient at infection onset, and these ﬁndings are
consistent with previous reports [12, 15, 28, 31]. The third
factor (and the only one that is potentially modiﬁable) was
inadequate empirical therapy. Its impact on mortality has
been widely documented, particularly in patients with BSIs
caused by extended-spectrum β-lactamase–producing Entero-
bacteriaceae [31–33]. However, in their recent study of a
cohort of 53 patients with KPC-Kp BSI, Zarkotou et al found
no correlation between outcome and the adequacy of the
initial antimicrobial regimen [15], and Patel et al reported
similar ﬁndings in 99 patients with invasive infections caused
by carbapenem-resistant Kp [34]. The discrepancy between
these ﬁndings and our own might stem from differences in
the size of the cohorts examined, the type of infections ana-
lyzed (eg, BSIs accounted for only about 60% of those report-
ed by Patel et al), and/or the minimal duration of survival
after BSI onset (ie, 48 hours of adequate treatment in all of
the patients we studied).
As for the nonempirical phase of treatment, our results
highlight the positive impact on outcome of a regimen that
includes >1 drug with in vitro activity against the isolate
(Figure 2). This ﬁnding is consistent with previous reports,
such as that by Hirsch and Tam, who reviewed 15 articles on
infections caused by KPC-producing isolates. In the 55 cases
analyzed in these papers, they found high rates of clinical
success in patients who received combination regimens in-
cluding a polymixin [10]. In the more recent study by Zarko-
tou et al, combinations of active antimicrobial drugs were also
signiﬁcantly associated with survival, but only in univariate
analysis, probably because of the small size of sample popula-
tion [15]. Our study, which included a larger sample of cases
of KPC-Kp BSI, reinforces concerns that monotherapy
regimens utilizing drugs with substantial potency or pharma-
cokinetic shortcomings for BSIs may be associated with in-
creased mortality.
Figure 1. Colistin, tigecycline, and gentamicin resistance rates among
Klebsiella pneumoniae isolates harboring the blaKPC-2 and blaKPC-3 genes.
Abbreviation: KPC, Klebsiella pneumoniae carbapenemase.
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Our multivariate analysis demonstrated that a triple-drug
regimen that included tigecycline, colistin, and meropenem
was signiﬁcantly linked to a reduced risk of death. Indeed, this
appeared to be the most effective approach to the treatment of
KPC-Kp BSIs, even when compared with other drug combina-
tions. In their review, Hirsch and Tam analyzed 11 KPC-Kp
infections (none of which were BSIs) treated with drug combi-
nations that included a polymyxin. The overall clinical success
rate was 73% (66% in the 6 patients treated with colistin plus
tigecycline) [10]. The percentages of our patients receiving co-
listin plus tigecycline in the survivor and nonsurvivor groups
did not differ signiﬁcantly (16/73 [21.9%] vs 7/52 [13.4%],
P = .22). In our entire cohort, the 30-day survival rate associat-
ed with this particular drug combination was 69.7% (16/23)
(vs 45.7% in patients who were treated with monotherapy),
but when meropenem was added to this regimen, survival in-
creased signiﬁcantly (87.5%).
This ﬁnding is unexpected because carbapenems are hydro-
lyzed by KPCs. However, in a recent review of the literature
(mostly case reports) on carbapenem treatment of infections
caused by carbapenemase-producing strains of Kp, Daikos
et al found that if the isolate had a carbapenem MIC of ≤4
mg/L, combined therapy with a carbapenem plus 1 other
active drug (an aminoglycoside or colistin or tigecycline) was
associated with signiﬁcantly lower mortality than combina-
tions of noncarbapenem drugs with in vitro activity, and these
ﬁndings were also in line with human pharmacokinetic/phar-
macodynamic data reviewed by the authors [11]. In our study,
improved survival was linked exclusively to the use of merope-
nem with tigecycline plus colistin, possibly because this was
the most common carbapenem-containing regimen used
in our patients. (Use of carbapenem-plus-aminoglycoside
combinations was much less frequent, probably because regi-
mens that included gentamicin were used only for BSIs caused
Table 2. Characteristics of Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae Bloodstream Infections Treated
With 1 vs >1 In Vitro–Active Antimicrobial Drug
Characteristic
No. (%) of Patients
Monotherapy
(n = 46)
Combination Therapy
(n = 79) P Value
Patient demographics
Male sex 26 (56.5) 47 (59.5) .75
Age, y, mean ± SD 65 ± 15 61 ± 16 .08
Ward
Medicine 18 (39.2) 26 (32.9) .48
Surgery 14 (30.4) 14 (17.7) .10
ICU 14 (30.4) 39 (49.4) .04
Comorbidities
Solid tumor 8 (17.4) 17 (21.5) .58
Hematological malignancy 2 (4.4) 11 (13.9) .09
Chronic renal failure 5 (10.9) 7 (8.9) .71
Diabetes mellitus 9 (19.6) 20 (25.3) .46
Charlson Comorbidity Index score, mean ± SD 2.5 ± 1.8 3 ± 1.9 .22
Immunosuppressive therapy 7 (15.2) 9 (11.4) .54
Clinical presentation
Source of infection
Central venous catheter 6 (13.0) 7 (8.9) .46
Lower respiratory tract 11 (26.1) 17 (21.5) .56
Urinary tract 10 (21.7) 7 (8.9) .04
Other 3 (6.5) 2 (2.5) .27
Unknown 24 (52.2) 51 (64.6) .17
Shock 8 (17.4) 9 (11.4) .35
APACHE III score, mean ± SD 30 ± 20 34 ± 21 .27
Isolates with suboptimal colistin/tigecycline MICsa 4 (8.6) 22 (27.9) .01
Data are expressed as No. (%) unless otherwise specified.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; MIC, minimum inhibitory concentration; SD, standard deviation.
a MICs at the upper limit of susceptibility for tigecycline (n = 18) or colistin (n = 8).
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by colistin-resistant isolates.) As shown in Table 4, when the
KPC-Kp isolate had a meropenem MIC of ≤4 mg/L, inclusion
of this drug in a combined-drug regimen was associated with
a survival rate of 86.6% (13/15). However, even when we
include patients with higher meropenem MICs in our analysis,
combined therapy that included meropenem produced a sur-
vival rate of 75%, and its performance in the subset with mer-
openem MICs≥ 16 mg/L was still better than average (64.7%
survival vs 58.3% in the entire 125-patient cohort). This is
consistent with the recent report that patients with KPC-Kp
BSIs who received colistin/polymyxin B or tigecycline mono-
therapy had signiﬁcantly higher mortality (66.7%) than those
treated with colistin/polymyxin B or tigecycline combined
with a carbapenem (12.5%) [35].
In conclusion, this triple-center retrospective study shows
that BSIs caused by Kp strains expressing KPC-2 or KPC-3
are associated with high 30-day mortality. Prompt administra-
tion of at least 1 antimicrobial drug with in vitro activity
against the isolate is essential in these cases. Indeed, even
though all of the patients included in this cohort received at
least 48 hours of this type of therapy, inadequate empirical
therapy was still a major predictor of 30-day mortality. As for
nonempirical therapy, combination therapy consisting of 2 or
3 active drugs seems to be more effective in terms of increas-
ing survival than use of only 1 active drug, and the most
signiﬁcant improvement seems to be obtained when the com-
bination includes a carbapenem. Although based on a relative-
ly small number of cases, this retrospective analysis indicates
that carbapenems provide therapeutic beneﬁt against KPC
producers when combined with tigecycline plus colistin.
Larger clinical prospective studies are needed to assess this
issue and to better deﬁne the importance of carbapenem
MICs in decisions related to the treatment of KPC-Kp BSIs.
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